Skip to main content
SpringerLink
Log in

Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR (2014) Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 4:527–537

    Article  CAS  Google Scholar 

  2. Conforti F, Wang Y, Rodriguez JA, Alberobello AT, Zhang YW, Giaccone G (2015) Molecular pathways: anticancer activity by inhibition of nucleocytoplasmic shuttling. Clin Cancer Res 21:4508–4513

    Article  CAS  Google Scholar 

  3. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28:155–165

    Article  CAS  Google Scholar 

  4. Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, Hanke T, Kauffman M, Shacham S, Reece D (2018) Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 131:855–863

    Article  CAS  Google Scholar 

  5. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727–738

    Article  CAS  Google Scholar 

  6. Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA (2019) Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol 186:549–560

    Article  CAS  Google Scholar 

  7. ClinicalTrials.gov Identifier: NCT03110562. at https://clinicaltrials.gov/ct2/show/NCT03110562). Accessed 14 June 2020

Download references

Funding

This study was funded by Karyopharm Therapeutics.

Author information

Authors and Affiliations

  1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    Tarek H. Mouhieddine

  2. Department of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 10 East 102nd Street, 6th Floor, New York, NY, 10029, USA

    Samir Parekh, Hearn Jay Cho, Joshua Richter, Ajai Chari, Sundar Jagannath & Deepu Madduri

  3. Karyopharm Therapeutics, Newton, MA, 02459, USA

    Andrew DeCastro, Jatin Shah & Yosef Landesman

Authors
  1. Tarek H. Mouhieddine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samir Parekh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hearn Jay Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew DeCastro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jatin Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yosef Landesman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ajai Chari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sundar Jagannath
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Deepu Madduri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepu Madduri.

Ethics declarations

Conflict of interest

S.P. received consulting fees from Foundation Medicine and research funding from Celgene and Karyopharm Therapeutics. H.J.C. received commercial research support from Genentech Roche, Celgene and Takeda, and compensation for consulting/advisory boards from Genentech Roche, Celgene, Bristol-Myers Squibb and GalaxoSmithKline, and is employed by the Multiple Myeloma Research Foundation. J.R. received speaking fees from Celgene and Janssen and an advisory board and consulting fees from Celgene, Janssen, Bristol-Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm Therapeutics, and Antengene. A.D. is an employee and stockholder of Karyopharm Therapeutics. J.S. is an executive and stockholder of Karyopharm Therapeutics. Y.L. is a senior VP and stockholder of Karyopharm Therapeutics. A.C. received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm Therapeutics, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, and Sanofi and has received research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals and Pharmacyclics. S. J. received advisory board fees and consulting fees from AbbVie, Celgene, Bristol-Myers Squibb, Karyopharm Therapeutics, Janssen Pharmaceuticals and Merck. D.M. received consulting fees from Janssen, Celgene, AbbVie, Takeda and Foundation Medicine. T.H.M. declares no potential conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mouhieddine, T.H., Parekh, S., Cho, H.J. et al. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Ann Hematol 100, 3057–3060 (2021). https://doi.org/10.1007/s00277-020-04293-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04293-y

Search

Navigation